Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M272Revenue $M81.1Net Margin (%)-54.5Z-Score-1.3
Enterprise Value $M189EPS $-1.7Operating Margin %-30.8F-Score4
P/E(ttm))0Cash Flow Per Share $-0.5Pre-tax Margin (%)-54.9Higher ROA y-yY
Price/Book2.610-y EBITDA Growth Rate %0Quick Ratio6.0Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %22.2Current Ratio6.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-18.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-55.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M104ROI % (ttm)-46.5Gross Margin Increase y-yN

Gurus Latest Trades with VVUS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VVUSJohn Burbank 2014-06-30 Sold Out -0.23%$4.59 - $6.18
($5.14)
$ 2.62-49%Sold Out0
VVUSJohn Burbank 2014-03-31 Reduce-1.37%$5.6 - $9.55
($7.2)
$ 2.62-64%Reduce -75.95%1,425,000
VVUSJohn Burbank 2013-12-31 Add0.15%$8.235 - $11.19
($9.67)
$ 2.62-73%Add 9.22%5,925,000
VVUSJohn Burbank 2013-09-30 Reduce-1.27%$9.45 - $14.99
($12.54)
$ 2.62-79%Reduce -36.22%5,425,000
VVUSJohn Burbank 2013-06-30 Reduce-0.46%$10.43 - $15.1
($12.91)
$ 2.62-80%Reduce -10.99%8,505,148
VVUSJean-Marie Eveillard 2013-06-30 Sold Out -0.01%$10.43 - $15.1
($12.91)
$ 2.62-80%Sold Out0
VVUSJohn Burbank 2013-03-31 Add0.27%$10.2 - $14.87
($12.43)
$ 2.62-79%Add 6.9%9,554,858
VVUSJean-Marie Eveillard 2013-03-31 Buy 0.01%$10.2 - $14.87
($12.43)
$ 2.62-79%New holding, 200000 sh.200,000
VVUSJohn Burbank 2012-12-31 Add0.8%$10.24 - $22.86
($14.58)
$ 2.62-82%Add 21.15%8,938,268
VVUSGeorge Soros 2012-09-30 Sold Out -0.06%$17.81 - $29.93
($23.45)
$ 2.62-89%Sold Out0
VVUSJohn Burbank 2012-06-30 Add0.73%$21.5 - $28.68
($24.02)
$ 2.62-89%Add 10.12%8,136,600
VVUSGeorge Soros 2012-06-30 Reduce-0.09%$21.5 - $28.68
($24.02)
$ 2.62-89%Reduce -64.93%150,000
VVUSJohn Burbank 2012-03-31 Add2.35%$9.99 - $23.78
($14.83)
$ 2.62-82%Add 72.22%7,388,793
VVUSGeorge Soros 2012-03-31 Buy 0.14%$9.99 - $23.78
($14.83)
$ 2.62-82%New holding, 427750 sh.427,750
VVUSGeorge Soros 2011-03-31 Sold Out $6.06 - $11.2
($7.95)
$ 2.62-67%Sold Out0
VVUSGeorge Soros 2010-12-31 Buy $5.94 - $9.78
($7.38)
$ 2.62-64%New holding, 19400 sh.19,400
VVUSDaniel Loeb 2010-06-30 Sold Out -0.62%$8.71 - $13.2
($10.68)
$ 2.62-76%Sold Out0
VVUSDaniel Loeb 2010-03-31 Buy 0.62%$8.24 - $10.54
($9.06)
$ 2.62-71%New holding, 1000000 sh.1,000,000
VVUSLee Ainslie 2008-12-31 Sold Out -0.01%$4.75 - $6.64
($5.7)
$ 2.62-54%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VVUS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


VVUS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanford Svai SCFO & Chief Accounting Officer 2015-01-29Sell472$2.78-5.76view
MARSH GUY PVP, US Operations & GM 2015-01-29Sell238$2.78-5.76view
Slebir John LSVP, Business Development & GC 2015-01-29Sell630$2.78-5.76view
Day WesleyVP, Clinical Development 2015-01-29Sell472$2.78-5.76view
NORTH TIDE CAPITAL, LLC10% Owner 2015-01-08Buy500,000$3.12-16.03view
NORTH TIDE CAPITAL, LLC10% Owner 2015-01-06Buy476,800$3.04-13.82view
NORTH TIDE CAPITAL, LLC10% Owner 2015-01-02Buy523,200$2.9-9.66view
Fischer Seth H.Z.CEO 2014-03-11Buy3,080$6.07-56.84view
DENNER ALEXANDER JDirector 2013-11-11Buy566,844$8.59-69.5view
MORRIS TIMOTHY EVP, Finance and CFO 2013-09-05Sell10,654$11.95-78.08view

Press Releases about VVUS :

    Quarterly/Annual Reports about VVUS:

    News about VVUS:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS Mar 25 2014 
    Billionaires Hold Four Stocks, 59% Off Sep 30 2013 
    Unique Investor Kyle Bass Unloads Five May 29 2013 
    Weekly Guru Bargains Highlights: FTE, VVUS, PAY, TIBX, VMW Feb 24 2013 
    Weekly Guru Bargains Highlights: FTNT, VVUS, HAE, PC, TIBX Dec 09 2012 
    Weekly Guru Bargains Highlights: CIG, PWE, VVUS, EBR, ATHN Dec 03 2012 
    Passport’s John Burbank Boosts VIVUS Stake to 8.5 Pct of Company Nov 02 2012 
    Weekly Top Insider Buys: IRM, JCP, APU, CAB, VVUS Aug 27 2012 
    Weekly CEO Sells Highlight: Splunk Inc, eBay Inc, Skyworks Solutions Inc, and VIVUS Inc. Jul 28 2012 

    More From Other Websites
    VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 29 2015
    VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile... Jan 29 2015
    VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile... Jan 29 2015
    7:00 am Vivus announces that the European Commissionhas adopted the commission implementing decision... Jan 29 2015
    VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 27 2015
    VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 26 2015
    Coverage initiated on Vivus by RBC Capital Mkts Jan 23 2015
    Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Jan 22 2015
    VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 15 2015
    VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 13 2015
    VIVUS to Present at Upcoming Investor Conference Jan 09 2015
    VIVUS to Present at Upcoming Investor Conference Jan 09 2015
    FDA clears Novo Nordisk's weight loss drug Saxenda Dec 23 2014
    FDA clears Novo Nordisk's weight loss drug Saxenda Dec 23 2014
    Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Dec 19 2014
    Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators Dec 19 2014
    Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Dec 17 2014
    VIVUS Announces Favorable Formulary Positioning for Qsymia Dec 15 2014
    VIVUS Announces Favorable Formulary Positioning for Qsymia Dec 15 2014
    Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Dec 12 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK